Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

777
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
777
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Barrett Esophagus-I: Introduction01:21

Barrett Esophagus-I: Introduction

613
Barrett's esophagus is a medical condition where the esophageal mucosa is significantly damaged by stomach acid or other digestive fluids, often due to long-term exposure associated with gastroesophageal reflux disease (GERD). In GERD, a weakened or abnormally relaxed lower esophageal sphincter allows stomach acid to flow persistently into the esophagus.
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more...
613
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

359
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
359
Esophageal Strictures-II: Clinical Features and Management01:26

Esophageal Strictures-II: Clinical Features and Management

417
Patients with esophageal strictures often experience a range of symptoms. Initially, they may have difficulty swallowing solid foods, which can progress to include liquids. Additional symptoms may involve chest pain or discomfort, regurgitating food and fluids, heartburn, unintentional weight loss, coughing or choking during meals, and hoarseness.
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
417
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

681
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
681

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting Phosphatidylserine in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas: A Phase 2 Trial of Bavituximab Plus Pembrolizumab with Biomarker-Correlated Outcomes.

Current oncology (Toronto, Ont.)·2026
Same author

Efficacy and Safety of <i>Bacillus coagulans</i> IDCC 1201 for Sleep Improvement in Adults with Sleep Disturbance: A Randomized, Double-Blind, Placebo-Controlled Polysomnographic Study.

Nutrients·2026
Same author

Best Treatment for Patients With Gastric Cancer Remains Uncertain-Reply.

JAMA·2026
Same author

Effects of a spore-forming probiotic blend on bowel habits and physical well-being in adults with functional constipation: A randomized, double-blind, placebo-controlled trial.

PloS one·2026
Same author

Comparison of Viable and Heat-Inactivated <i>Lacticaseibacillus rhamnosus</i>IDCC 3201: Anti-Pathogenic, Anti-Inflammatory, and Microbiota Modulating Effect.

Food science & nutrition·2026
Same author

Gastric Cancer: A Review.

JAMA·2026

Related Experiment Video

Updated: Jan 13, 2026

Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

756

Targeting Esophageal Cancer: Promising Drugs for the Clinical Landscape and Key Knowledge Gaps.

Terzungwe Akumaga1, Haeseong Park2, A Craig Lockhart3

  • 1Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.

Drug Design, Development and Therapy
|January 8, 2026
PubMed
Summary

Esophageal cancer treatment is advancing with biomarker-driven therapies. Key biomarkers like HER2 and PD-L1 guide personalized treatment for advanced esophageal adenocarcinoma (EAC), improving patient outcomes.

Keywords:
Gastroesophagealimmunotherapytargeted therapytumor microenvironment

More Related Videos

Subculture and Cryopreservation of Esophageal Adenocarcinoma Organoids: Pros and Cons for Single Cell Digestion
10:42

Subculture and Cryopreservation of Esophageal Adenocarcinoma Organoids: Pros and Cons for Single Cell Digestion

Published on: July 6, 2022

4.2K
Establishment and Histological Analysis of Esophageal Organoids Modeling the Progression from Normal to Cancerous Tissues
05:57

Establishment and Histological Analysis of Esophageal Organoids Modeling the Progression from Normal to Cancerous Tissues

Published on: May 30, 2025

966

Related Experiment Videos

Last Updated: Jan 13, 2026

Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

756
Subculture and Cryopreservation of Esophageal Adenocarcinoma Organoids: Pros and Cons for Single Cell Digestion
10:42

Subculture and Cryopreservation of Esophageal Adenocarcinoma Organoids: Pros and Cons for Single Cell Digestion

Published on: July 6, 2022

4.2K
Establishment and Histological Analysis of Esophageal Organoids Modeling the Progression from Normal to Cancerous Tissues
05:57

Establishment and Histological Analysis of Esophageal Organoids Modeling the Progression from Normal to Cancerous Tissues

Published on: May 30, 2025

966

Area of Science:

  • Oncology
  • Gastroenterology
  • Translational Medicine

Background:

  • Esophageal cancer presents a significant global health challenge with poor survival rates for metastatic disease.
  • Tumor heterogeneity and resistance limit conventional chemotherapy efficacy.
  • Biomarker-driven therapies offer personalized treatment strategies for esophageal cancer.

Purpose of the Study:

  • To review current clinical strategies for esophageal cancer, focusing on biomarker-directed therapies.
  • To summarize pivotal trials and emerging treatments for advanced esophageal adenocarcinoma (EAC).
  • To discuss challenges and future research directions in esophageal cancer therapy.

Main Methods:

  • Narrative review of clinical strategies and biomarker-directed therapies for esophageal cancer.
  • Emphasis on clinically validated biomarkers: HER2, PD-L1, CLDN18.2, and MMR/MSI status.
  • Inclusion of data from pivotal Phase II/III trials and early-phase studies of novel therapies.

Main Results:

  • Biomarkers HER2, PD-L1, CLDN18.2, and MMR/MSI status are crucial for therapeutic selection in advanced esophageal cancer.
  • Biomarker-directed therapies, particularly for EAC, have transformed treatment paradigms.
  • Emerging modalities like antibody-drug conjugates show promise, linked to specific biomarkers.

Conclusions:

  • Biomarker-driven approaches are revolutionizing esophageal cancer management, especially for EAC.
  • Ongoing research is vital to address tumor heterogeneity, resistance, and develop novel therapies.
  • Future directions include improving biomarkers and targeting tumor vulnerabilities for better outcomes.